We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 468

The Potential Impact of the Supreme Court’s Decision in Oil States
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • November 23 2017

On November 27, 2017, in Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, the Supreme Court will hold oral argument to determine the


Actavis, Teva and Generics ta Mylan v ICOS and Eli Lilly: Dosage patent for tadalafil for treatment of male erectile dysfunction held invalid for obviousness on appeal
  • Bird & Bird
  • United Kingdom
  • November 2 2017

The Court of Appeal has warned against over-elaboration of the “obvious to try” line of cases and demonstrated that, in a case which involves routine


PTAB Grants Rare Request for Additional Discovery In IPR
  • Foley & Lardner LLP
  • USA
  • October 26 2017

In Mylan v. Allergan (IPR2016-00127, Paper No. 73), the PTAB granted a rare request for discovery filed be Petitioner in response to summaries of data


Healthcare Post-Mortem: Medical Industry Continues to be High-Value Target for FCA Enforcement
  • Vinson & Elkins LLP
  • USA
  • October 18 2017

Last week we gave you the bottom line of how much DOJ (and relators) recovered in FY 2017. As we promised, we are doing a series of sector-specific


Further Venue Guidance for Patent Infringement Suits
  • Gordon Rees Scully Mansukhani
  • USA
  • October 6 2017

As anticipated, the Supreme Court’s May 22, 2017 TC Heartland LLC v. Kraft Foods Group Brands LLC, 581 U.S. ____ (2017) ruling, which recognized 28 U


Indian Tribal Sovereign Immunity Asserted in an IPR
  • Seyfarth Shaw LLP
  • USA
  • September 25 2017

The America Invents Act (“AIA”) provides for post grant challenges of U.S. patents in the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent


Recent Trends on the U.S. Doctrine of Equivalents
  • Sterne Kessler Goldstein & Fox PLLC
  • USA
  • September 19 2017

U.S. courts have long recognized that a product or process which does not literally infringe a patent can nevertheless infringe under the "doctrine of


The Four Things That Surprised Us in the EpiPen False Claims Settlement
  • Mintz Levin
  • USA
  • August 23 2017

On August 17, 2017, the U.S. Department of Justice (DOJ) announced that it had reached a $465 million false claims settlement with Mylan, the


EpiPen Maker Mylan Gets Stuck With $465 Million Fine; Politicians Say it Doesn’t Sting Enough
  • Cadwalader Wickersham & Taft LLP
  • USA
  • August 21 2017

After years of defrauding the U.S. government and taxpayers, Mylan, the maker of EpiPen, last week resolved allegations that it profited at the


The Federal Circuit Weighs in on the Doctrine of Equivalents for Chemical Inventions
  • K&L Gates
  • USA
  • July 31 2017

In Mylan Institutional LLC v. Aurobindo Pharma Ltd., he Federal Circuit affirmed the district court granting a preliminary injunction based on